...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >Effect of pilsicainide on dominant frequency in the right and left atria and pulmonary veins during atrial fibrillation: association with its atrial fibrillation terminating effect.
【24h】

Effect of pilsicainide on dominant frequency in the right and left atria and pulmonary veins during atrial fibrillation: association with its atrial fibrillation terminating effect.

机译:心房颤动中比西卡尼对左右心房和肺静脉显性频率的影响:及其终止心房颤动的作用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Dominant frequency reflects the peak cycle length of atrial fibrillation. In 34 patients with atrial fibrillation, bipolar electrograms were recorded from multiple atrial sites and pulmonary veins and the effect of pilsicainide, class Ic antiarrhythmic drug, on dominant frequency was examined. At baseline, mean dominant frequencies (Hz) in the right and left atria, coronary sinus and right and left superior pulmonary veins were 5.87 +/- 0.76, 6.08 +/- 0.60, 5.65 +/- 0.95, 6.12 +/- 0.88 and 6.59 +/- 0.89, respectively (P < 0.05, left superior pulmonary vein vs right atrium and coronary sinus). After pilsicainide (1.0 mg/kg/5 min), dominant frequency decreased at all sites in all patients. Atrial fibrillation was terminated at 5.9 +/- 2.2 min in 16 patients (Group A) with a decrease in the average of mean dominant frequencies at all sites from 5.80 +/- 0.72 to 3.57 +/- 0.63 Hz, was converted to atrial flutter at 7.3 +/- 1.4 min in 5 (Group B) with a decrease in the average dominant frequency from 5.83 +/- 0.48 to 3.08 +/- 0.19 Hz, and was not terminated in the other 13 (Group C) despite the average dominant frequency decrease from 6.59 +/- 0.76 to 4.42 +/- 0.52 Hz. In 14 of the 21 Groups A and B patients (67%), mean dominant frequencies at all recording sites were < 4.0 after pilsicainide, while they were < 4.0 in 1 of the 13 Group C patients (8%, P < 0.01). In conclusion, the degree of dominant frequency decrease by pilsicainide is closely related to its atrial fibrillation terminating effect: When dominant frequency in the atria decreases to < 4.0 Hz, atrial fibrillation is terminated with 93% positive and 63% negative predictive values.
机译:主导频率反映了心房纤颤的峰值周期长度。在34例房颤患者中,从多个心房部位和肺静脉记录了双极电描记图,并检查了pilsicainide(Ic类抗心律不齐药物)对显性频率的影响。在基线时,左右心房,冠状窦和左右上肺静脉的平均优势频率(Hz)为5.87 +/- 0.76、6.08 +/- 0.60、5.65 +/- 0.95、6.12 +/- 0.88和分别为6.59 +/- 0.89(P <0.05,左上肺静脉vs右心房和冠状窦)。用比西卡尼(1.0 mg / kg / 5 min)治疗后,所有患者所有部位的显性频率均下降。 16名患者(A组)在5.9 +/- 2.2分钟时终止房颤,所有部位的平均平均主导频率从5.80 +/- 0.72降低至3.57 +/- 0.63 Hz,转换为房扑5组(B组)的频率为7.3 +/- 1.4分钟,平均主导频率从5.83 +/- 0.48降低至3.08 +/- 0.19 Hz,并且在其他13组(C组)中,尽管平均主频率从6.59 +/- 0.76降低到4.42 +/- 0.52 Hz。在21例A和B组患者中,有14例(67%)在比西卡尼治疗后所有记录位点的平均显性频率均<4.0,而在13例C组患者中有1例的平均显性频率<4.0(8%,P <0.01)。综上所述,比西卡尼降低显性频率的程度与其终止心房纤颤的效果密切相关:当心房中的显性频率降低至<4.0 Hz时,心房纤颤终止,其阳性预测值为93%,阴性预测值为63%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号